Quantitative structure-activity relationship to elucidate human CYP2A6 inhibition by organosulfur compounds

Daniela A Ramirez1, Eduardo J Marchevsky2, Juan M Luco2

  • 1Instituto de Biología Agrícola de Mendoza (IBAM), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Almirante Brown 500, Chacras de Coria, Mendoza, Argentina.

ADMET & DMPK
|March 30, 2022
PubMed

Insights

Researchers explored how organosulfur compounds interact with CYP2A6, an enzyme crucial for nicotine metabolism and carcinogen activation. This study aids in designing new anti-smoking therapies and reducing cancer risks from tobacco compounds.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Pharmacology

Background:

  • CYP2A6 is a key human enzyme in nicotine metabolism and tobacco-specific procarcinogen activation.
  • Inhibiting CYP2A6 shows potential for anti-smoking therapies and reducing carcinogen risks.
  • Understanding CYP2A6 interactions is vital for drug design.

Purpose of the Study:

  • To investigate the interactions between organosulfur compounds and the CYP2A6 enzyme.
  • To utilize Quantitative Structure-Activity Relationship (QSAR) analysis for modeling these interactions.
  • To provide insights for designing novel CYP2A6 inhibitors from dietary compounds.

Main Methods:

  • Quantitative Structure-Activity Relationship (QSAR) analysis was employed.
  • Multiple Regression Analysis (MLR) and Partial Least Squares (PLS) techniques were used for data modeling.
  • Evaluation of interactions between organosulfur compounds and CYP2A6.

Main Results:

  • Hydrophobic and steric factors significantly influence the binding of organosulfur compounds to CYP2A6.
  • Electronic factors play a crucial role, particularly in the case of monosulfides.
  • QSAR models successfully predicted the activity of these compounds.

Conclusions:

  • The study elucidates the key structural determinants for CYP2A6 inhibition by organosulfur compounds.
  • Findings support the development of dietary compounds as potential CYP2A6 inhibitors.
  • This research contributes to the rational design of agents for smoking cessation and cancer risk reduction.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.4K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.3K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
1.3K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
512